{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:57:26Z","timestamp":1775901446080,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T00:00:00Z","timestamp":1415664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["5288"],"award-info":[{"award-number":["5288"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2015,3,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Allogeneic stem cell transplantation (SCT) remains the standard treatment for advanced chronic myeloid leukemia (CML) and Philadelphia chromosome\u2013positive acute lymphoblastic leukemia (Ph<jats:sup>+<\/jats:sup>ALL). Relapsed disease is the major cause of treatment failure, especially when SCT is given in the setting of advanced disease. Tyrosine kinase inhibitors can be given after transplantation prophylactically or after the detection of minimal residual disease (MRD) to reduce the relapse risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Posttransplant nilotinib was started after the achievement of sustained engraftment and the resolution of transplant\u2010related toxicities. Nilotinib was continued until progression or unacceptable toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Twenty\u2010two patients with advanced CML (n\u2009=\u200915) or Ph<jats:sup>+<\/jats:sup>ALL (n\u2009=\u20097) underwent SCT with human leukocyte antigen\u2013matched siblings (n\u2009=\u200911), unrelated donors (n\u2009=\u20097), or alternative donors (n\u2009=\u20094). Sixteen patients were given prophylactic nilotinib maintenance, which was started at a median of 38 days after transplantation. Six patients stopped the treatment because of toxicities (mostly gastrointestinal and hepatic). After nilotinib maintenance, 11 patients achieved (n\u2009=\u20099) or maintained (n\u2009=\u20092) a complete molecular response (CMR), and only 1 of them later relapsed. Four of the 5 patients not achieving CMR relapsed. At a median follow\u2010up of 46 months, 9 patients were alive, and 13 had died. The 2\u2010year overall and progression\u2010free survival rates were 55% (95% confidence interval [CI], 34%\u201075%) and 45% (95% CI, 25%\u201066%), respectively. Among the 16 nilotinib recipients, the rates were 69% (95% CI, 46%\u201092%) and 56% (95% CI, 32%\u201081%), respectively. The 2\u2010year nonrelapse mortality and relapse rates for all patients were 32% (95% CI, 17%\u201058%) and 23% (95% CI, 11%\u201049%), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Nilotinib is relatively safe and effective prophylactic therapy for the prevention of relapse after SCT. It may control MRD and convert patients to CMR, which is associated with prolonged survival. These observations merit further study in larger scale studies. <jats:bold><jats:italic>Cancer<\/jats:italic> 2015;121:863\u2013871.<\/jats:bold> \u00a9 <jats:italic>2014 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.29141","type":"journal-article","created":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T10:27:09Z","timestamp":1415701629000},"page":"863-871","source":"Crossref","is-referenced-by-count":53,"title":["Phase 1\/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or <scp>P<\/scp>hiladelphia chromosome\u2013positive acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"121","author":[{"given":"Avichai","family":"Shimoni","sequence":"first","affiliation":[{"name":"Division of Hematology and Bone Marrow Transplantation Chaim Sheba Medical Center Tel\u2010Hashomer Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia","family":"Volchek","sequence":"additional","affiliation":[{"name":"Division of Hematology and Bone Marrow Transplantation Chaim Sheba Medical Center Tel\u2010Hashomer Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Koren\u2010Michowitz","sequence":"additional","affiliation":[{"name":"Division of Hematology and Bone Marrow Transplantation Chaim Sheba Medical Center Tel\u2010Hashomer Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nira","family":"Varda\u2010Bloom","sequence":"additional","affiliation":[{"name":"Division of Hematology and Bone Marrow Transplantation Chaim Sheba Medical Center Tel\u2010Hashomer Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raz","family":"Somech","sequence":"additional","affiliation":[{"name":"Division of Hematology and Bone Marrow Transplantation Chaim Sheba Medical Center Tel\u2010Hashomer Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noga","family":"Shem\u2010Tov","sequence":"additional","affiliation":[{"name":"Division of Hematology and Bone Marrow Transplantation Chaim Sheba Medical Center Tel\u2010Hashomer Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronit","family":"Yerushalmi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Bone Marrow Transplantation Chaim Sheba Medical Center Tel\u2010Hashomer Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[{"name":"Division of Hematology and Bone Marrow Transplantation Chaim Sheba Medical Center Tel\u2010Hashomer Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.708753"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402808"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-141689"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-031682"},{"key":"e_1_2_7_7_1","first-page":"1145","article-title":"Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia","volume":"91","author":"Perz JB","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.160"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.04.036"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22778"},{"key":"e_1_2_7_11_1","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long\u2010term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"91","author":"Gratwohl A","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.08.019"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403068"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.11.026"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0580"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.3110"},{"key":"e_1_2_7_17_1","first-page":"663","article-title":"A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation","volume":"91","author":"Weisser M","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705167"},{"key":"e_1_2_7_19_1","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1182\/blood.V89.7.2602","article-title":"Detection of bcr\u2010abl transcripts in Philadelphia chromosome\u2013positive acute lymphoblastic leukemia after marrow transplantation","volume":"89","author":"Radich J","year":"1997","journal-title":"Blood"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.9.2632.bloodjournal8592632"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3320"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high\u2010risk Philadelphia chromosome\u2013positive leukemia","volume":"109","author":"Carpenter PA","year":"2007","journal-title":"Blood"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1746"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011221"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.08.011"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.352"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.253"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25351"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.5"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404318"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000228587"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000314538"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.05.017"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.12.587"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0000000000000186"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-082990"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29141","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.29141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:26:10Z","timestamp":1760275570000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.29141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,11]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,3,15]]}},"alternative-id":["10.1002\/cncr.29141"],"URL":"https:\/\/doi.org\/10.1002\/cncr.29141","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,11]]}}}